A Phase I/II Study of the Tolerability of Lenalidomide and Low Dose Dexamethasone in Previously Treated Multiple Myeloma Patients With Impaired Renal Function
Multiple Myeloma (MM) affects approximately 20,000 Americans annually and remains an
incurable hematologic malignancy characterized by frequent early response followed by
universal treatment relapse necessitating multiple sequential therapeutic regimens. Until
recently, few effective therapies existed. Several novel agents for MM have now become
available including the immunomodulatory drugs thalidomide, lenalidomide, as well as the
proteasome inhibitor, bortezomib. Each of these agents is undergoing extensive clinical
evaluation in combination with other therapies to produce unprecedented response rates in
newly diagnosed and relapsed MM. Lenalidomide has proven to be a highly effective treatment
agent, particularly when used in combination with dexamethasone but is renally excreted and
little information is available about its use in myeloma patients with impaired kidney
function (20% have renal failure at some time after diagnosis). Defining a safe and
effective dose of lenalidomide to use is a critical step in MM treatment.
OUTLINE: This is a Phase I, dose-escalation study of lenalidomide followed by a Phase II
study. Patients are stratified according to degree of renal dysfunction (moderate
[creatinine clearance 30-60 mL/min] vs severe [creatinine clearance <30 mL/min and does not
require dialysis] vs end-stage renal disease [creatinine clearance <30 mL/min and requires
dialysis]).
Patients receive oral lenalidomide on days 1-21 and low-dose oral dexamethasone 40 mg on
days 1, 8, 15, and 22. There is a 7 day rest (days 22-28) from lenalidomide. Each cycle is
28 days and repeated in the absence of disease progression or unacceptable toxicity.
Patients enrolled in the phase II portion of the study will undergo blood sample collection
periodically for pharmacokinetic analysis of lenalidomide (Mayo Clinic sites only).
After completion of study treatment, patients are followed every 6 months for up to 3 years.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Maximum tolerated dose of lenalidomide (Phase I)
Phase I-Establish the maximum tolerated dose of lenalidomide in each of three groups of myeloma patients with impaired renal function.
15 months
Yes
Joseph R. Mikhael, MD
Study Chair
Mayo Clinic
United States: Food and Drug Administration
PrE1003
NCT00790842
December 2008
January 2016
Name | Location |
---|---|
Mayo Clinic | Rochester, Minnesota 55905 |
Marquette General Hospital | Marquette, Michigan 49855 |
Reading Hospital and Medical Center | Reading, Pennsylvania 19612-6052 |
Hackensack University Medical Center | Hackensack, New Jersey 07601 |
Kinston Medical Specialists | Kinston, North Carolina 28501 |
Mayo Clinic in Arizona | Scottsdale, Arizona 85259-5404 |
University of Pennsylvania | Philadelphia, Pennsylvania 19104 |
McFarland Clinic | Ames, Iowa 50010 |
Gundersen Lutheran | La Crosse, Wisconsin 54601 |
Metro MN CCOP | Minneapolis, Minnesota 55416 |
Siouxland Hematology Oncology Associates | Sioux City, Iowa 51101 |
Missouri Valley Cancer Consortium | Omaha, Nebraska 68106 |
Emory University Winship Cancer | Atlanta, Georgia 30322 |
University of IL at Chicago | Chicago, Illinois 60612 |
WVU Mary Babb Randolph Cancer Center | Morgantown, West Virginia 26506 |
Waukesha Memorial Hospital (ProHealth Care) | Waukesha, Wisconsin 53188 |
Michigan Cancer Research Consortium and Oncology Research- St. Joseph Mercy Hospital - Ann Arbor | Ann Arbor, Michigan 48106-0955 |